MedTrace Logo

An Evaluation of LY007 Cell Injection for r/r B-NHL

NCT06279611 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-02-28

No results posted yet for this study

Summary

An evaluation of LY007 cell injection for recurrent/refractory CD20 was positive Tolerability, safety, and efficacy of B-cell non-Hodgkin lymphoma in open, single-arm Phsea I Clinical research

Conditions

  • B-NHL

Interventions

DRUG

LY007

FC and LY007 infusion

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • Ruijin Hospital

    collaborator OTHER

  • Shanghai Longyao Biotechnology Inc., Ltd.

    lead OTHER

Principal Investigators

  • Zhao Weili, MD · Ruijin Hospital, Shanghai Jiaotong University School of Medicine Recruiting Shanghai, Shanghai, China, 200025

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-25
Primary Completion
2024-08-31
Completion
2026-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06279611 on ClinicalTrials.gov